The new trading week kicks in with Ebix (Nasdaq: EBIX) reporting its fourth-quarter results in the morning. Ebix provides on-demand enterprise software for the insurance industry. Analysts see earnings climbing by 10% to $0.33 a share. Ebix has grown at a healthier clip in the past, but it's also landed well ahead of where the analysts were perched in each of the past four quarters.

It'll be retailers on parade come Tuesday, as footwear chain DSW (NYSE: DSW) and women's-apparel specialist rue21 (NYSE: RUE) provide a mall's-eye view of how the economy did during the Christmas season. Both retailers are expected to post solid bottom-line growth.

(NYSE: GES) and SciClone Pharmaceuticals (Nasdaq: SCLN) head up Wednesday's class of quarterly reporters.

Guess? is the apparel juggernaut. SciClone is a profitable biotech, making the most of its hepatitis B treatment that's been approved for sale in China. Both companies are targeted to improve on their previous year's profitability.

Ross Stores
(Nasdaq: ROST) runs the popular chain of discount department stores. Ross naturally thrived during the recession, when shoppers were pinching their pennies. It seems to be doing well now that folks are only pinching their dimes and quarters.

The final trading day of the week finds Harris & Harris (Nasdaq: TINY) offering investors a quarterly peek into its incubator. Harris & Harris is a venture-capital company that buys into promising nanotech and microsystem specialists.

Until next week, I remain,

Rick Munarriz

See a stock in this story you'd like to follow? Add it to My Watchlist, which will find all of our Foolish analysis on it.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.